Generic Drugs & Pharmacy News
Humira manufacturer AbbVie and Amgen, maker of Humira biosimilar Amjevita (sometimes spelled Amgevita), have reached a settlement that will allow the biosimilar to launch â€” but not for several years.Â
The drug had U.S. sales of approximately $350 million for the 12 months ending July 2017, according to QuintilesIMS data.Â
SILVER SPRING, Md. â€” The Food and Drug Administration has approved the first generic from Taiwan-based drug development company Sunny Pharmtech and generic development company Vitruvias Therapeutics. The companies announced the approval of its generic lidocaine ointment, 5%.
The drug marks another approval for Tevaâ€™s generic injectable business, which the company has been focused on growing.Â
The product is indicated to relieve various corticosteroid-responsive dermatoses in patients ages 18 years and older.
The drug is an opioid indicated to manage moderate to severe pain in patients requiring continuous around-the-clock pain opioid analgesia for an extended period of time.
Jim Loerop with lead the company's business development and mergers and acquisitions functions as the company ramps up its move into the complex generics and specialty branded segments.
The acne treatment had U.S. sales of roughly $57 million for the 12 months ended July 2017, Perrigo said.